Pyxis Oncology, Inc. (PYXS)

Pyxis Oncology, Inc., based in Cambridge, Massachusetts, is a preclinical-stage biopharmaceutical company specializing in the development of innovative therapies for cancer treatment. Founded in 2018, Pyxis Oncology is focused on advancing a diverse portfolio of product candidates designed to target various types of cancers through novel mechanisms of action. The company's research and development efforts are primarily centered on immune-oncology and antibody-drug conjugate (ADC) platforms, aimed at addressing significant unmet medical needs in oncology.

The company's leading immune-oncology product candidate, PYX-106, is a fully human immunoglobulin G1 (IgG1) isotype antibody targeting Siglec-15. PYX-106 is under investigation for its potential to treat a range of solid tumors, including thyroid cancer, head and neck squamous cell carcinoma, and non-small cell lung cancer (NSCLC). This investigational therapy aims to modulate the immune system's response to cancer cells by targeting the Siglec-15 pathway, a novel approach that may enhance anti-tumor immunity.

In addition to PYX-106, Pyxis Oncology is developing PYX-102, another investigational immune-therapeutic designed to address solid tumors. PYX-102 aims to leverage immune modulation strategies to improve therapeutic outcomes in oncology. The company also focuses on developing a robust pipeline of antibody-drug conjugates (ADCs) that combine the targeting capabilities of antibodies with potent cytotoxic agents to selectively destroy cancer cells.

The ADC portfolio includes PYX-201, an investigational novel ADC targeting NSCLC, breast cancer, and other solid tumors; PYX-202, designed for small cell lung cancer (SCLC), soft tissue sarcoma, and additional solid tumors; and PYX-203, targeting acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). These ADCs are engineered to deliver targeted therapy directly to cancer cells, potentially enhancing efficacy while minimizing off-target effects. Through its innovative approaches and cutting-edge research, Pyxis Oncology aims to bring transformative new treatments to cancer patients, advancing the frontiers of oncology therapeutics.